ClinicalTrials.gg
RecruitingNCT06763952Updated Oct 22, 2026

Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes

An interventional study of AI-BRIDGE and Educational Materials in Diabetic Retinopathy and Diabetes Mellitus, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 22, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6,900
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 54 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Planned enrollment
3rd of 196
6,900 · median 72
Started
2026
with 18 others
No phase
53 of 267
10 open now
Primary completion
2030-05
later than 49 of 52 live
Registered
240th of 267
by date
Lead sponsor
6 of 267
University of Wisconsin, Madison

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 3rd largest by planned enrollment of the 196 interventional ones that give a count, is one of 19 that started in 2026, is one of 53 with no phase, reaches primary completion later than 49 of the 52 other live ones, and was the 240th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

This pragmatic clinical trial is being conducted to test the effectiveness of AI-BRIDGE (Artificial Intelligence-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education), in improving screening and follow-up eye care compared to usual-care among patients with diabetes across 8 primary care clinics. AI-BRIDGE is an implementation program which includes an autonomous AI-based protocol that provides screening for diabetic retinopathy (DR) disease at primary care visits, as well as patient education on disease and, if a patient screens positive for referable DR or has insufficient quality image, or image unobtainable due to other technical issues, or does not get AI-screening for any reason, assistance with scheduling an in-person, follow-up eye-care visit.

Read the detailed description

This study is a parallel cluster randomized clinical trial to determine whether AI-BRIDGE, an autonomous AI-based protocol of screening for DR, improves DR screening and follow-up rates compared to usual care. In this study, DR screening refers to the detection of DR either via referral of patients for an eye-care appointment with an eye-care provider in usual-care or via point-of-care AI-based DR screening for patients in AI-BRIDGE. The trial will be conducted across 8 clinics from four health systems that are Federally Qualified Health Centers. Each clinic will be randomly assigned to either usual care or the AI-BRIDGE intervention.

Randomization is done at the clinic level in this study. One of the two clinics within each of the four health systems will be randomly selected to be in the AI-BRIDGE arm (i.e., a total of four clinics will use AI-BRIDGE during the intervention period) and the other clinics will be in the control arm (i.e., a total of four clinics will be in usual care).

Primary Objective:

Compare the proportion of patients who follow-up with recommended eye care in the AI-BRIDGE and usual-care arms within 6 months of primary care visit.

Secondary Objective:

Compare the proportion of patients who complete DR screening, defined as: (AI-BRIDGE) an AI-interpretable image obtained at the primary care visit; or, for patients who did not complete AI screening or did not start AI-screening, an in-person screening eye care visit completed within 6 months of the primary care visit; (Usual-care) an in-person screening eye care visit completed within 6 months of the primary care visit.

03

Conditions studied

  • Diabetic Retinopathy
  • Diabetes Mellitus

Keywords

  • Artificial Intelligence
  • AI
  • diabetic eye disease
  • cluster randomized trial
  • pragmatic trial
  • eye screening
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Clinics Inclusion Criteria:

  • Clinic must be from a health system with at least two clinics that meet eligibility criteria and will agree to join.
  • Number of unique patients with diabetes should be >550 over any continuous 15-month period prior to the clinic providing a letter of support to participate in the trial.
  • No point-of-care screening system in use for DR.
  • Have an electronic health record to track patient data and agree to share limited data set as requested.
  • Have a member of the clinical team who can commit to serving as the clinic champion for this study.
  • Have the IT infrastructure to deploy an artificial-intelligence-based eye camera in the clinic.

Patient Inclusion Criteria:

  • Diagnosis of type 1 or 2 diabetes
  • No known diabetic retinopathy
  • No diabetic retinopathy screening in the past 12 months

Patient Exclusion Criteria:

  • Have a documented DR screening in the electronic health record within 12 months of the date of the primary care visit
  • includes diagnosed with macular edema, severe non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy, or retinal vein occlusion
  • Pregnant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6,900 participants (estimated)

Study arms

  • Active comparator
    Health System 1: Usual Care plus Education

    4 month period of usual care screening then randomized to a 15-month period of usual care. Participants in usual care will receive educational material about diabetic retinopathy.

    Other: Educational Materials

  • Experimental
    Health System 1: AI-BRIDGE Clinic

    4 month period of usual care screening then randomized to a 15-month period of AI-based eye screening program called AI-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education (AI-BRIDGE).

    Other: AI-BRIDGE

  • Active comparator
    Health System 2: Usual Care plus Education

    4 month period of usual care screening then randomized to a 15-month period of usual care. Participants in usual care will receive educational material about diabetic retinopathy.

    Other: Educational Materials

  • Experimental
    Health System 2: AI-BRIDGE Clinic

    4 month period of usual care screening then randomized to a 15-month period of AI-based eye screening program called AI-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education (AI-BRIDGE).

    Other: AI-BRIDGE

  • Active comparator
    Health System 3: Usual Care plus Education

    4 month period of usual care screening then randomized to a 15-month period of usual care. Participants in usual care will receive educational material about diabetic retinopathy.

    Other: Educational Materials

  • Experimental
    Health System 3: AI-BRIDGE Clinic

    4 month period of usual care screening then randomized to a 15-month period of AI-based eye screening program called AI-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education (AI-BRIDGE).

    Other: AI-BRIDGE

  • Active comparator
    Health System 4: Usual Care plus Education

    4 month period of usual care screening then randomized to a 15-month period of usual care. Participants in usual care will receive educational material about diabetic retinopathy.

    Other: Educational Materials

  • Experimental
    Health System 4: AI-BRIDGE Clinic

    4 month period of usual care screening then randomized to a 15-month period of AI-based eye screening program called AI-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education (AI-BRIDGE).

    Other: AI-BRIDGE

Interventions

  • OtherAI-BRIDGE

    AI-BRIDGE intervention includes (1) acquisition of eye photos and autonomous (i.e. without human oversight) AI-based identification of referable or non-referable DR or insufficient image at the primary care clinic, (2) provision of patient educational material identical to that provided to the usual-care group, and (3) clinic champion-led assistance with scheduling eye-care follow-up visits for patients with referable DR or has insufficient quality image, or image unobtainable due to other technical issues, or does not get AI-screening for any reason.

    Also known as: Artificial Intelligence-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education

  • OtherEducational Materials

    Participants in the Usual Care arm will receive educational materials about diabetic retinopathy during the intervention period.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Who Follow Up With Recommended Eye Care

    Proportion of patients who follow-up with recommended eye care in the AI-BRIDGE and usual-care arms within 6 months of primary care visit.

    Time frame: up to 6 months

Secondary outcomes

  1. Proportion of patients who complete DR screening

    Proportion of patients who complete DR screening, defined as: (AI-BRIDGE) an AI-interpretable image obtained at the primary care visit; or, for patients who did not complete AI screening or did not start AI-screening, an in-person screening eye care visit completed within 6 months of the primary care visit; (Usual-care) an in-person screening eye care visit completed within 6 months of the primary care visit.

    Time frame: up to 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The trial protocol and SAP will be publicly accessible through the Harvard Dataverse, where study protocols, analysis code, and related project documentation will be deposited and assigned DOIs. In addition, summary protocol information, and aggregate trial data, along with related metadata, will be available on ClinicalTrials.gov in accordance with clinical trial reporting requirements.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data from this study may be requested from other researchers up to 7 years after the completion of the primary outcome by contacting Dr. Roomasa Channa, the PI of this study.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for May 2030, 43 months after the start.

Of 111 non-industry interventional studies with no phase under Diabetic Retinopathy, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's planned 43 months is above that.

Counting every sponsor, half of 126 studies reached it within 29 months; a quarter within 11 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2024
First posted
Jan 8, 2025
StartActual
Oct 1, 2026
Primary completionEst.
May 2030
CompletionEst.
May 2030
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 22, 2026
Sites
UW School of Medicine and Public Health is now Recruiting
Oct 22, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionProportion of Participants Who Follow Up With Recommended Eye Care: how it is measured was reworded
Oct 2, 2026
Show all 2 updates
  1. Oct 22, 2026
    Not yet recruiting→Recruiting
    UW School of Medicine and Public Health is now Recruiting
    + 2 other changes: verification date and date precision
  2. Oct 2, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionProportion of Participants Who Follow Up With Recommended Eye Care: how it is measured was reworded
    + 2 other changes: identifiers and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06763952
Responsible party
Sponsor
First posted
Jan 8, 2025
Start date
Oct 1, 2026
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
Last update
Oct 22, 2026

Study contacts

Mozhdeh Bahrainian
Contact
bahrainian@wisc.edu
608-262-9955
Roomasa Channa
Contact
rchanna@wisc.edu
Roomasa Channa
principal investigator · UW School of Medicine and Public Health

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion